Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells

Journal of Drug Targeting

Volumn 20, Issue 5, 2012, Pages 422-432

  Mamot, Christoph ^a,b   Ritschard, Reto ^a   Wicki, Andreas ^a   Küng, Willy ^a   Schuller, Jan ^c   Herrmann, Richard ^a   Rochlitz, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

^c SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

Author keywords

EGFR; Immunoliposomes; Liposomes; Mdr; Multi drug resistance

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOLIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOLIPOSOME DRUG DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861064878     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.680960     Document Type: Article

References (32)

1. Abdul-Ghani R, Serra V, Györffy B, Jürchott K, Solf A, Dietel M, Schäfer R. (2006). The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene, 25, 1743-1752.
2. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R. (1996). Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res, 56, 3010-3020. (Pubitemid 26199746)
3. Bier H, Hoffmann T, Hauser U, Wink M, Ochler M, Kovar A, Müser M, Knecht R. (2001). Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer ChemotherPharmacol, 47, 519-524. (Pubitemid 32477299)
4. Cole SP, Deeley RG. (1998). Multidrug resistance mediated by the ATPbinding cassette transporter protein MRP. Bioessays, 20, 931-940. (Pubitemid 28554038)
5. Dalquen P, Moch H, Feichter G, Lehmann M, Solèr M, Stulz P, Jordan P, Torhorst J, Mihatsch MJ, Sauter G. (1997). DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in nonsmall- cell lung carcinoma. Virchows Arch, 431, 173-179. (Pubitemid 27440361)
6. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 26, 5705-5712.
7. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA. (2008). Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci USA, 105, 12128-12133.
8. Fan Z, Masui H, Altas I, Mendelsohn J. (1993). Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res, 53, 4322-4328. (Pubitemid 24146785)
9. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. (1992). Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res, 52, 6774-6781. (Pubitemid 23006277)
10. Juranka PF, Zastawny RL, Ling V. (1989). P-glycoprotein: multidrugresistance and a superfamily of membrane-associated transport proteins. FASEB J, 3, 2583-2592. (Pubitemid 20013272)
11. Kellen JA. (1994). The Phenomenon of multi drug resistance. In: Kellen JA, ed. Reversal of Multidrug Resistance in Cancer. Boca Raton, FL: CRC Press, 1-21.
12. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. (1997). Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry, 36, 66-75. (Pubitemid 27024679)
13. Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH. (2007). A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res, 13, 3276-3285. (Pubitemid 46944913)
14. Lasic DD. (1992). Mixed micelles in drug delivery. Nature, 355, 279-280.
15. Leonard GD, Fojo T, Bates SE. (2003). The role of ABC transporters in clinical practice. Oncologist, 8, 411-424. (Pubitemid 37238869)
16. Leonard GD, Polgar O, Bates SE. (2002). ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs, 3, 1652-1659. (Pubitemid 36266743)
17. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. (2003a). Epidermal growth factor receptor (EGFR)- targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII- overexpressing tumor cells. Cancer Res, 63, 3154-3161. (Pubitemid 36735867)
18. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. (2003b). Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat, 6, 271-279. (Pubitemid 37493783)
19. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. (2005). Epidermal growth factor receptortargetedimmunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res, 65, 11631-11638. (Pubitemid 41821723)
20. Mamot C, Ritschard R, Küng W, Park JW, Herrmann R, Rochlitz CF. (2006). EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J Drug Target, 14, 215-223.
21. Mickley L, Fojo AT. (1998). The MDR genes. In: Pinedo HM, Giaccone G, eds. Drug Resistance in the Treatment of Cancer. Cambridge, MA: Cambridge University Press, 101-131.
22. Nobili S, Landini I, Giglioni B, Mini E. (2006). Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets, 7, 861-879.
23. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. (2004). Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets, 8, 335-353. (Pubitemid 39117698)
24. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C,Shalaby R, Kotts C, Wood WI. (1995). Development of antip185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA, 92, 1327-1331.
25. Pereira E, Teodori E, Dei S, Gualtieri F, Garnier-Suillerot A. (1995). Reversal of multidrug resistance by verapamil analogues. Biochem Pharmacol, 50, 451-457.
26. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. (2005). Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapyresistant, advanced breast carcinoma. Cancer, 104, 682-691. (Pubitemid 41114904)
27. Renes J, de Vries EG, Jansen PL, Müller M. (2000). The (patho) physiological functions of the MRP family. Drug Resist Updat, 3, 289-302.
28. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. (1988). Evaluation of a solubletetrazolium/ formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res, 48, 4827-4833.
29. Stupp R, Bauer J, Pagani O, Gerard B, Cerny T, Sessa C, Bastian G, Sarkany M, Schläpfer J, Giroux B, Leyvraz S. (1998). Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Ann Oncol, 9, 1233-1242. (Pubitemid 28552814)
30. Szoka F, Olson F, Heath T, Vail W, Mayhew E, Papahadjopoulos D. (1980). Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporationand extrusion through polycarbonate membranes. Biochim Biophys Acta, 601, 559-571.
31. Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C. (2012). Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res, 18, 454-464.
32. Wosikowski K, Schuurhuis D, Kops GJ, Saceda M, Bates SE. (1997). Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res, 3, 2405-2414. (Pubitemid 28133162)